NASDAQ:ABCL AbCellera Biologics Q3 2026 Earnings Date & Estimates $12.37 -0.24 (-1.90%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$12.06 -0.31 (-2.53%) As of 10/14/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. AbCellera Biologics is scheduled to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for 5:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026TimeAfter Market ClosesConference Call5:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from AbCellera Biologics in Q3 2026AbCellera Biologics is expected to post earnings of -$0.1757 per share on revenue of $6.25 million. In the same quarter a year earlier AbCellera Biologics reported -$0.19 per share on revenue of $6.51 million. AbCellera Biologics last reported on August 5, 2026, posting -$0.18 per share and missing the -$0.1640 consensus estimate. AbCellera Biologics has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.1757Expected Revenue$6.25 millionPrior-Year EPS-$0.19Prior-Year Revenue$6.51 millionExpected Revenue Growth-4.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.18 (Missed by -$0.0160)Last Quarter Revenue$4.05 millionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report AbCellera Biologics Q3 2026 Earnings FAQ When does AbCellera Biologics report Q3 2026 earnings? AbCellera Biologics (NASDAQ:ABCL) has confirmed it will report Q3 2026 earnings on Monday, November 9, 2026, after market closes. What time is AbCellera Biologics' Q3 2026 earnings call? AbCellera Biologics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for AbCellera Biologics? Analysts expect AbCellera Biologics to post earnings of -$0.1757 per share for Q3 2026. How much revenue is AbCellera Biologics expected to report? The consensus revenue estimate for AbCellera Biologics is $6.25 million for Q3 2026. AbCellera Biologics Earnings HeadlinesAbCellera Biologics' ABCL635 Seen With Best-in-Class Potential in Menopause, UBS SaysOctober 13 at 2:16 PM | finance.yahoo.comUBS Initiates AbCellera Biologics at Buy With $18 Price TargetOctober 12 at 1:46 PM | marketscreener.comMReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. | Base Camp Trading (Ad)AbCellera Biologics (NASDAQ:ABCL) Coverage Initiated by Analysts at UBS GroupOctober 12 at 9:06 AM | americanbankingnews.comAbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws FocusOctober 9, 2026 | finance.yahoo.comAbCellera to Present Phase 1/2 ABCL635 Data at Menopause Society MeetingOctober 9, 2026 | marketscreener.comMSee More AbCellera Biologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AbCellera Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AbCellera Biologics and other key companies, straight to your email. Email Address About AbCellera BiologicsAbCellera Biologics (NASDAQ:ABCL) is a biotechnology company that develops technologies for the discovery and development of antibody medicines. Its platform combines high-throughput screening, single-cell analysis, microfluidics, data science and machine learning to identify antibodies with potential therapeutic applications. The company works with pharmaceutical and biotechnology partners worldwide, helping them discover and advance antibody candidates for areas such as cancer, infectious diseases, autoimmune disorders and other medical conditions. AbCellera provides access to its discovery platform, laboratory capabilities and scientific expertise, while also pursuing selected internal drug development programs. Founded in 2012 and headquartered in Vancouver, British Columbia, AbCellera has supported antibody discovery programs for partners in multiple global markets. Its technology contributed to the discovery of bamlanivimab, an antibody treatment developed with Eli Lilly for COVID-19. Carl Hansen, one of the company’s co-founders, serves as its president and chief executive officer.View AbCellera Biologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
